 |
|
Treatment of Chronic Granulocytic Leukemia with Myleran
JOHN LOUIS, M.D.;
LOUIS R. LIMARZI, M.D.;
WILLIAM R. BEST, M.D.
AMA Arch Intern Med. 1956;97(3):299-308.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
In the hope of finding a less toxic analogue of nitrogen mustard, Haddow replaced the methyl groups in the nitrogen mustard molecule with various aromatic radicals. The compounds which were synthesized were not as effective as nitrogen mustard. Since the effect of nitrogen mustards is thought to be related to its ability to alkylate (i. e., exchange its halogen radical for some unknown body constituent), Timmis substituted another alkylating radical, sulfonic acid ester, for the halogen group. He synthesized a series of disulfonic ester molecules having various carbon chains. The four and five carbon chains were found to be most effective against the Walker rat carcinoma 256.1
Galton first reported the effects of 1,4-bis (methylsulfonoxy) butane (Myleran) in human leukemia.* After two years of experience in 19 patients with chronic granulo- cytic leukemia he reported clinical improvement similar to that obtained with x-ray therapy. Myleran was not found to
. . . [Full Text PDF of this Article]
Author Affiliations
Chicago
From the Hematology Section of the Department of Medicine, University of Illinois, College of Medicine. Technical assistance was given by Adelle M. Frost.
Footnotes
Received for publication Aug. 19, 1955.
Burroughs Wellcome & Company, Inc., furnished us with Myleran for clinical trials.
Supported by research grant C-2347R PET, from the National Cancer Institute of the National Institute of Health, Public Health Service.
Read before the Section on Pathology and Physiology at the 104th Annual Meeting of the American Medical Association, Atlantic City, June 8, 1955.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
